US4743679A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for producing human epidermal growth factor and analogs thereof
Assignee: Curis Inc
•
Filing: 1986-02-24
•
Granted: 1988-05-10
•
Expires: 2006-02-24
Abstract
Abstract Disclosed is a process for producing a fusion protein comprising epidermal growth factor (EGF) attached through a Glu-residue to a leader. Treatment of the fusion protein with a Staphylococcus aureus V8 protease specific for cleaving peptides at a Glu-linkage produces large amounts of the 53 amino acid EGF sequence. The treatment conditions optimize production of the 53 and 51 amino acid EGFs relative to shorter analogs, and take full advantage of the selectivity of the protease.
Inventors
- 👤 Charles M. Cohen
- 👤 Roberto Crea
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 08:01
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/70; C12N15/71; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/485; C12N15/11; C12N15/62; C12N15/625; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/50; C07K2319/70; C07K2319/74; C07K2319/75; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S435/848; Y10S435/849; Y10S930/00; Y10S930/01; Y10S930/12; Y10S930/26; Y10S930/30
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
136 words
A fused peptide compound having the formula: X-Glu-EGF wherein X is a leader sequence oligopeptide which serves to promote expression of said fused peptide compound in a selected cellular host, Glu is a linking glutamyl residue, and EGF is the amino acid sequence of an epidermal growth factor or an active analog thereof comprising between 42 and 53 amino acids, wherein the sequence of the first 42 amino acids of said analog is homologous with that of a native epidermal growth factor, said EGF being attached at its N-terminal end to said linking Glu residue, and said linking Glu residue being attached to the C-terminal end of said leader sequence oligopeptide, said peptide compound being cleavable by Staph A protease to separate X from EGF to produce an active EGF having at least 42 amino acids.
Claim 2
Dependent Claim
136 words
A fused peptide compound having the formula: X-Glu-EGF wherein X is a leader sequence oligopeptide which serves to promote expression of said fused peptide compound in a selected cellular host, Glu is a linking glutamyl residue, and EGF is the amino acid sequence of an epidermal growth factor or an active analog thereof comprising between 42 and 53 amino acids, wherein the sequence of the first 42 amino acids of said analog is homologous with that of a native epidermal growth factor, said EGF being attached at its N-terminal end to said linking Glu residue, and said linking Glu residue being attached to the C-terminal end of said leader sequence oligopeptide, said peptide compound being cleavable by Staph A protease to separate X from EGF to produce an active EGF having at least 42 amino acids.
Claim 3
Dependent Claim
18 words
The peptide of claim 1 wherein EGF is the 53 amino acid sequence of native epidermal growth factor.
Claim 4
Dependent Claim
26 words
The peptide of claim 1 wherein EGF is the amino acid sequence of epidermal growth factor minus the 52 Leu residue and the 53 Arg residue.
Claim 5
Dependent Claim
16 words
The peptide of claim 1 wherein X has the amino acid sequence: ______________________________________
MetAlaLysAsnLeuAsnAspAlaAlaLysAsnLeu
AsnAspAlaAlaLysAsnLeuAsnAspAlaAsp.
______________________________________
Claim 6
Dependent Claim
19 words
The peptide compound of claim 1 wherein X is a leader sequence oligopeptide of up to 75 amino acids.
Claim 7
Dependent Claim
19 words
The peptide compound of claim 1 wherein X is a leader sequence oligopeptide of up to 200 amino acids.
References Cited (Backward Citations)
US3917824A
Cited
US4338397A
Cited
EP0046039A1
Cited
GB2092155A
Cited
WO1983004030A1
Cited
EP0128733A1
Cited
WO1985000369A1
Cited
EP0131868A1
Cited
EP0136490A2
Cited
WO1985001284A1
Cited
EP0150572A1
Cited
JPS60130397A
Cited
JPS60130393A
Cited
EP0147178A2
Cited
GB2162851A
Cited
JPS61185197A
Cited
EP0177915A2
Cited
WO1986002271A1
Cited
JPS61167625A
Cited
GB2172890A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-05-10 | 1991-11-09 | 1992-05-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-05-10 | 1995-11-09 | 1996-05-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-05-10 | 1999-11-09 | 2000-05-10 | $7700.00 | Window Closed / Lapsed |